0001088020-11-000023.txt : 20110303 0001088020-11-000023.hdr.sgml : 20110303 20110303165606 ACCESSION NUMBER: 0001088020-11-000023 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110301 FILED AS OF DATE: 20110303 DATE AS OF CHANGE: 20110303 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PALATIN TECHNOLOGIES INC CENTRAL INDEX KEY: 0000911216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954078884 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 4C CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 609-495-2200 MAIL ADDRESS: STREET 1: 4C CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: INTERFILM INC DATE OF NAME CHANGE: 19930825 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILLS STEPHEN T CENTRAL INDEX KEY: 0001103883 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15543 FILM NUMBER: 11660894 MAIL ADDRESS: STREET 1: PALATIN TECHNOLOGIES, INC. STREET 2: 4C CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 4 1 primary_doc.xml PRIMARY DOCUMENT X0303 4 2011-03-01 0 0000911216 PALATIN TECHNOLOGIES INC PTN 0001103883 WILLS STEPHEN T PALATIN TECHNOLOGIES, INC. 4C CEDAR BROOK DRIVE CRANBURY NJ 08512 0 1 0 0 Exec VP - Operations & CFO common stock 2011-03-01 4 P 0 50000 A 98024 D Series A common stock purchase warrant 1 2011-03-01 4 P 0 4348 A 2011-03-01 2016-03-01 common stock 4348 4348 D Series B common stock purchase warrant 1 2011-03-01 4 P 0 45652 A 2012-03-02 2017-03-02 common stock 45652 45652 D Included in the purchase of 50,000 Units at a price of $1.00 per Unit. Each Unit consisted of one share of common stock; a Series A Warrant exercisable immediately for 2/23 of a share of common stock at an exercise price of $1.00 per share, with an expiration date of March 1, 2016; and a Series B Warrant exercisable starting March 2, 2012 for 21/23 of a share of common stock at an exercise price of $1.00 per share, with an expiration date of March 2, 2017. Exercise of the Series B warrant is subject to stockholder approval of an increase in the issuer's authorized capital. Stephen T. Wills 2011-03-03